Business Wire

Celltrion to Launch Both Antigen and Antibody Testing Kits in the U.S.

Share

Celltrion Group (KRX:068270) today announced the launch of two rapid kits for SARS-CoV-2 in the US by the third week of August.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200811005863/en/

SAMPINUTE™ COVID-19 Antigen MIA (left) and DiaTrust™ COVID-19 IgG/IgM Rapid Test (Photo: Business Wire)

SAMPINUTE™ COVID-19 Antigen MIA (left) and DiaTrust™ COVID-19 IgG/IgM Rapid Test (Photo: Business Wire)

SAMPINUTETM COVID-19 Antigen MIA is an electrochemical immunoassay test for detection of SARS-CoV-2 antigen from nasopharyngeal swab samples, composed of one time use test cartridges and a portable analyzer developed in collaboration with BBB1.

DiaTrustTM COVID-19 IgG/IgM Rapid Test is a one-step in-vitro diagnostic test based on immunochromatographic assay designed for the rapid detection of antibodies of the novel coronavirus in healthcare settings in collaboration with Humasis2.

Both SAMPINUTETM COVID-19 Antigen MIA (antigen test) and DiaTrustTM COVID-19 IgG/IgM Rapid Test (antibody test) have shown reliable performance and promising clinical trial results. SAMPINUTETM COVID-19 Antigen MIA has a sensitivity of 94% and a specificity of 100%, with time to results within 10 minutes.

DiaTrustTM COVID-19 IgG/IgM Rapid Test also shows reliable performance with 96% positive percent agreement and 98.67% negative percent agreement for IgM, 92% positive percent agreement and 100% negative percent agreement for IgG. The turnaround time is 15 minutes.

Celltrion requested Emergency Use Authorization (EUA) for SAMPINUTETM COVID-19 Antigen MIA on July 24th, and for DiaTrustTM COVID-19 IgG/IgM Rapid Test on July 8th. The rapid tests kits are currently under the review of the US Food and Drug Administration’s Emergency Use Authorization. Celltrion anticipates the FDA EUA approval and subsequent commercialization in the US market by mid-August.

Celltrion is also developing a potential antiviral treatment for COVID-19 with its phase I clinical study initiated on July 17th.

Celltrion plans to launch the second generation antibody and antigen tests, in collaboration with the DiaTrustTM COVID-19 IgG/IgM Rapid Test’s manufacturer Humasis, for which Celltrion will apply its proprietary COVID-19 antibody-antiviral technology to enhance detection sensitivity during the second half of 2020.

“Celltrion has been striving to bring the tests into the US. The need for more accessible, affordable, and most importantly, rapid diagnostic testing will grow, as the daily activities are coming back, and the economy is opening up again,” a Celltrion representative stated. “With the short turnaround time and promising performance of the sensitivity and specificity results, Celltrion is confident that both SAMPINUTETM COVID-19 Antigen MIA and DiaTrustTM COVID-19 IgG/IgM Rapid Test will add great value to healthcare providers in screening patients and keeping communities safe.”

About Celltrion, Inc

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in the research, development and manufacture of small molecules, biosimilars and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for INFLECTRA® and Remsima®, respectively, the world’s first mAb biosimilar approved from regulatory agencies in developed countries. For more information, visit www.celltrion.com.

FORWARD LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance, and future events or developments involving Celltrion/Celltrion USA, Inc. that may constitute forward-looking statements under pertinent securities laws.

These statements may be identified by words such as “prepares,” “hopes to,”“upcoming,” ”plans to,” “aims to,” “to be launched,” “is preparing,” “once gained,” “could,” “with the aim of,” “may,”“once identified,” “will,” “working towards,” “is due,” “become available,”“has potential to,” the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make forward-looking oral statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion USA, Inc.'s management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance, and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion USA, Inc. believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion USA, Inc. undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

1 For more information, visit https://www.bbbtech.com/

2 For more information, visit http://humasis.com/

Contact information

Celltrion, Inc.
Eunyoung Lee, +82 32 850 4384
Eunyoung.lee1@celltrion.com
Or
Tae-Gyun Kim, +82 32 850 5136
Taegyun.kim@celltrion.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Atlas Holdings Acquires Permasteelisa Group30.9.2020 11:15:00 CESTPress release

Atlas Holdings announced today that it has completed its acquisition of Permasteelisa Group, a global leader in the engineering, project management, manufacturing, installation and after-sales service of advanced building facades, architectural envelopes and interiors. Permasteelisa Group has partnered with architects on more than 3,500 projects that have transformed skylines around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930005357/en/ Permasteelisa Group’s three brands, Permasteelisa, Gartner and Scheldebouw, are recognized as the premier integrated providers of high quality, bespoke curtain wall solutions in the world. Collectively, the company employs more than 4,500 associates, designing, fabricating and installing premier projects out of locations in 30 countries, including nine production facilities and eight principal design offices. “Permasteelisa Group is trusted by the world’s most visionary ar

Orange Polska Leverages ADTRAN’s Fiber Extension Solutions to Extend FTTH Services30.9.2020 11:00:00 CESTPress release

https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fportal.adtran.com%2Fweb%2Fpage%2Fportal%2FAdtran%2Fwp_home&esheet=52297558&newsitemid=20200930005145&lan=en-US&anchor=ADTRAN%26%23174%3B%2C+Inc.&index=1&md5=a2f44128c043e79907dc3239808d7aba ADTRAN®, Inc., (NASDAQ:ADTN), the leading provider of next-generation open networking and subscriber experience solutions, today announced its deployment plans with Orange Polska. Orange, Poland’s leading operator with 28% market share and over 13.7 million active customers, is rapidly rolling out its Fiber-to-the-Home (FTTH) service and has selected https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.adtran.com%2Findex.php%2Fbroadband-access%2Fg-fast&esheet=52297558&newsitemid=20200930005145&lan=en-US&anchor=ADTRAN%26%238217%3Bs+2nd+Generation+Gfast+fiber+extension+solutions&index=3&md5=52a7e862db7c4f566a3e3be6b8e5e7a6 ADTRAN’s 2nd Generation Gfast fiber extension solutions to further accelerate its delivery of high

New Denodo Platform 8.0 Accelerates Hybrid/Multicloud Integration, Automates Data Management with AI/ML, and Boosts Performance30.9.2020 08:00:00 CESTPress release

Denodo, the leader in data virtualization, today announced that its new Denodo Platform version 8.0 accelerates hybrid/multicloud integration, automates data management with artificial intelligence (AI)/machine learning (ML), and boosts performance with smart query acceleration. By further augmenting the Denodo Platform’s already advanced data integration, management, and delivery capabilities with intelligent recommendations, hyper performance, and PaaS support, Denodo Platform 8.0 advances data virtualization into a logical data fabric. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005427/en/ “Data fabric is a hot, emerging market that delivers a unified, intelligent, and integrated end-to-end platform to support new and emerging use cases,” wrote Noel Yuhanna, VP and principal analyst at Forrester Research, and author of https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.denodo.com%2Fen%2Fforrest

Verimatrix Application Shielding Technology Wins CSI Magazine Award30.9.2020 07:15:00 CESTPress release

Regulatory News: Verimatrix, (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that ProtectMyApp, an application shielding solution for mobile app developers, was named Best Cybersecurity Service in the 18th Annual CSI Magazine Awards. Winners were announced during a virtual broadcast on September 18. Verimatrix’s application shielding technology is routinely recognized for its ability to streamline the implementation of code protection while still providing the most robust security possible for mobile app developers. “It’s crucial to vigorously secure the actual mobile applications that have become such a vital part of our industry,” said Goran Nastic, editor of CSI Magazine. “Delivering increasingly valuable content, mobile apps and their developers can be armed with latest application shielding technologies that result in self-defending apps. Congratulations to Verimatrix for being named the winner of

Aurora Sustainability: Changing the World With the Network Effect30.9.2020 07:00:00 CESTPress release

«Be the change you want to see in the world,» is a well-worn cliché. However, most of us feel overwhelmed in the face of the climate and environmental challenges. Instead of giving in, Cape Town-based Danielle Laity and her team decided to do something. They’ve started a new community: Aurora Sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005910/en/ Danielle Laity's new sustainable network, Aurora Sustainability, started in Cape Town, and has already over 10.000 users. Credit: Miris (Photo: Business Wire) “In Cape Town, we feel the need for a more sustainable and fairer world every day. Food security is an issue, the predominantly fossil fuel based electrical grid is under strain and climate change will only exacerbate these problems” says Danielle Laity. On the Aurora community platform, anyone can log on and take a quick quiz that tells you the size of your carbon footprint. The intention is not to co

CellSafe and Dynasty Castle Investments Limited Signed Distribution Agreement for LAMPlex TM RT-qLAMP COVID-19 Detection Assay30.9.2020 06:44:00 CESTPress release

CellSafe, a specialist in developing diagnostics located at the Republic of Korea and Dynasty Castle Investments Limited, a Hong Kong based company specializing in the procurement, distribution and delivery of medical supplies, today announced that they have signed an exclusive distribution agreement for Portugal and 6 African countries for the sale and distribution of LAMPlexTM RT-qLAMP COVID-19 Detection Assay, real-time reverse transcription loop-mediated isothermal amplification (LAMP) technology-based kit which can detect the novel corona virus within 25 minutes. DCI has the rights to supply this clinically proven, reliable FAST molecular diagnostic kit in such countries in partnership with its local distributors. As this global pandemic is raging across the world, CellSafe has cooperated with Armed Forces Medical Research Institute, Republic of Korea to develop and launch LAMPlexTM RT-qLAMP COVID-19 Detection Assay. “This unprecedented pandemic is affecting our lives everywhere.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom